Exelixis Inc
Change company Symbol lookup
Select an option...
EXEL Exelixis Inc
ATOM Atomera Inc
IEAWW Infrastructure and Energy Alternatives 27 March 2023 *W EXP 03/27/2023
SLAC Social Leverage Acquisition Corp I
CNNXF Cannamerica Brands Corp
BA Boeing Co
COP Conocophillips
XOM Exxon Mobil Corp
BP BP PLC
KMI Kinder Morgan Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Price
Delayed
$21.19
Day's Change
0.365 (1.75%)
Bid
--
Ask
--
B/A Size
--
Day's High
21.41
Day's Low
20.72
Volume
(Light)

Today's volume of 484,389 shares is on pace to be much lighter than EXEL's 10-day average volume of 3,398,612 shares.

484,389

Upcoming Events

EXEL's fiscal year ends in December
There are no upcoming events for EXEL

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
May 10, 2022Q1 2022 Earnings Release$0.21$0.07 to $0.21$0.00
February 17, 2022Q4 2021 Earnings Release$0.29-$0.04 to $0.17$0.09
November 2, 2021Q3 2021 Earnings Release$0.12-$0.03 to $0.23-$0.10
August 5, 2021Q2 2021 Earnings Release$0.30$0.03 to $0.10$0.21

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.